MX2021015325A - Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa. - Google Patents
Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa.Info
- Publication number
- MX2021015325A MX2021015325A MX2021015325A MX2021015325A MX2021015325A MX 2021015325 A MX2021015325 A MX 2021015325A MX 2021015325 A MX2021015325 A MX 2021015325A MX 2021015325 A MX2021015325 A MX 2021015325A MX 2021015325 A MX2021015325 A MX 2021015325A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrazole compounds
- disubstituted pyrazole
- ketohexokinase inhibitors
- formula
- ketohexokinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
La presente invención proporciona un compuesto de la Fórmula I: (ver Fórmula) o una sal farmacéuticamente aceptable del mismo. y el uso de los compuestos de la Fórmula I para el tratamiento de afecciones metabólicas. tales como la diabetes mellitus tipo 2. la insuficiencia cardíaca. la enfermedad renal diabética y la esteatohepatitis no alcohólica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962862382P | 2019-06-17 | 2019-06-17 | |
US202062975887P | 2020-02-13 | 2020-02-13 | |
PCT/US2020/037894 WO2020257171A1 (en) | 2019-06-17 | 2020-06-16 | Disubstituted pyrazole compounds as ketohexokinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021015325A true MX2021015325A (es) | 2022-01-18 |
Family
ID=71950812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021015325A MX2021015325A (es) | 2019-06-17 | 2020-06-16 | Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa. |
Country Status (22)
Country | Link |
---|---|
US (2) | US11124500B2 (es) |
EP (1) | EP3983404B1 (es) |
JP (2) | JP6986653B2 (es) |
KR (1) | KR20220008882A (es) |
CN (1) | CN114008036A (es) |
AU (1) | AU2020295979A1 (es) |
BR (1) | BR112021023153A2 (es) |
CA (1) | CA3143490C (es) |
CL (1) | CL2021003342A1 (es) |
CO (1) | CO2021016870A2 (es) |
CR (1) | CR20210600A (es) |
EC (1) | ECSP21091203A (es) |
ES (1) | ES2961283T3 (es) |
IL (1) | IL288350A (es) |
JO (1) | JOP20210329A1 (es) |
MA (1) | MA56208A (es) |
MX (1) | MX2021015325A (es) |
PE (1) | PE20220377A1 (es) |
TW (1) | TWI750685B (es) |
UA (1) | UA126847C2 (es) |
WO (1) | WO2020257171A1 (es) |
ZA (1) | ZA202109067B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021129817A1 (zh) * | 2019-12-25 | 2021-07-01 | 南京明德新药研发有限公司 | 具有果糖激酶(khk)抑制作用的嘧啶类化合物 |
US20240067633A1 (en) * | 2020-12-25 | 2024-02-29 | Sichuan Haisco Pharmaceutical Co., Ltd. | Ketohexokinase inhibitor and use thereof |
US20230079863A1 (en) * | 2021-03-29 | 2023-03-16 | Gilead Sciences, Inc. | Khk inhibitors |
WO2022211595A1 (ko) * | 2021-04-01 | 2022-10-06 | 주식회사 엘지화학 | 옥사디아졸 화합물 및 이를 포함하는 약제학적 조성물 |
WO2023121378A1 (ko) * | 2021-12-24 | 2023-06-29 | 주식회사 엘지화학 | (s)-2-(2-메틸아제티딘-1-일)피리미딘 유도체 및 이를 포함하는 약제학적 조성물 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101111247B1 (ko) * | 2009-07-17 | 2012-06-12 | 한국과학기술연구원 | Ros 카이네이즈 저해활성을 갖는 피라졸 화합물 |
US10093668B2 (en) * | 2015-10-28 | 2018-10-09 | Northwestern University | Substituted aromatic N-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (Mnk1) and 2 (Mnk2) |
SI3397631T1 (sl) * | 2015-12-29 | 2022-01-31 | Pfizer Inc. | Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze |
TWI714231B (zh) * | 2018-09-04 | 2020-12-21 | 美商美國禮來大藥廠 | 2,6-二胺基吡啶化合物 |
-
2020
- 2020-06-03 TW TW109118557A patent/TWI750685B/zh active
- 2020-06-16 UA UAA202106634A patent/UA126847C2/uk unknown
- 2020-06-16 CA CA3143490A patent/CA3143490C/en active Active
- 2020-06-16 ES ES20751803T patent/ES2961283T3/es active Active
- 2020-06-16 BR BR112021023153A patent/BR112021023153A2/pt not_active Application Discontinuation
- 2020-06-16 AU AU2020295979A patent/AU2020295979A1/en not_active Abandoned
- 2020-06-16 EP EP20751803.6A patent/EP3983404B1/en active Active
- 2020-06-16 MA MA056208A patent/MA56208A/fr unknown
- 2020-06-16 PE PE2021001989A patent/PE20220377A1/es unknown
- 2020-06-16 US US16/902,806 patent/US11124500B2/en active Active
- 2020-06-16 CN CN202080044683.4A patent/CN114008036A/zh active Pending
- 2020-06-16 KR KR1020217040905A patent/KR20220008882A/ko not_active Application Discontinuation
- 2020-06-16 JO JOP/2021/0329A patent/JOP20210329A1/ar unknown
- 2020-06-16 MX MX2021015325A patent/MX2021015325A/es unknown
- 2020-06-16 WO PCT/US2020/037894 patent/WO2020257171A1/en unknown
- 2020-06-16 CR CR20210600A patent/CR20210600A/es unknown
- 2020-06-16 JP JP2021510724A patent/JP6986653B2/ja active Active
-
2021
- 2021-09-17 US US17/478,080 patent/US20220017496A1/en active Pending
- 2021-11-15 ZA ZA2021/09067A patent/ZA202109067B/en unknown
- 2021-11-24 IL IL288350A patent/IL288350A/en unknown
- 2021-11-29 JP JP2021192979A patent/JP7221367B2/ja active Active
- 2021-12-13 CO CONC2021/0016870A patent/CO2021016870A2/es unknown
- 2021-12-14 CL CL2021003342A patent/CL2021003342A1/es unknown
- 2021-12-17 EC ECSENADI202191203A patent/ECSP21091203A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020257171A1 (en) | 2020-12-24 |
BR112021023153A2 (pt) | 2022-01-04 |
TW202112768A (zh) | 2021-04-01 |
JP2022031816A (ja) | 2022-02-22 |
US20200392118A1 (en) | 2020-12-17 |
ES2961283T3 (es) | 2024-03-11 |
EP3983404B1 (en) | 2023-08-09 |
PE20220377A1 (es) | 2022-03-16 |
CL2021003342A1 (es) | 2022-09-09 |
JOP20210329A1 (ar) | 2023-01-30 |
CR20210600A (es) | 2022-01-11 |
US11124500B2 (en) | 2021-09-21 |
JP7221367B2 (ja) | 2023-02-13 |
UA126847C2 (uk) | 2023-02-08 |
IL288350A (en) | 2022-01-01 |
CN114008036A (zh) | 2022-02-01 |
MA56208A (fr) | 2022-04-20 |
CA3143490C (en) | 2024-03-05 |
ZA202109067B (en) | 2023-06-28 |
EP3983404A1 (en) | 2022-04-20 |
KR20220008882A (ko) | 2022-01-21 |
JP2021525793A (ja) | 2021-09-27 |
TWI750685B (zh) | 2021-12-21 |
ECSP21091203A (es) | 2022-01-31 |
CO2021016870A2 (es) | 2022-01-17 |
JP6986653B2 (ja) | 2021-12-22 |
CA3143490A1 (en) | 2020-12-24 |
US20220017496A1 (en) | 2022-01-20 |
AU2020295979A1 (en) | 2021-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021015325A (es) | Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa. | |
PH12021550449A1 (en) | 2,6-diamino pyridine compounds. | |
EP4302826A3 (en) | Glucagon-like peptide 1 receptor agonists | |
BR112023001195A2 (pt) | Composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto pró-fármaco do mesmo, composto, método de preparação para composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto de pró-fármaco, composição farmacêutica, método para tratar uma doença associada com a ativação do caminho alternativo de complemento, e, uso do composto | |
MX2022001784A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos. | |
MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
AU2021285747A8 (en) | LPA receptor antagonists and uses thereof | |
AU2020288567A8 (en) | Pyrrolopyrimidine compound and use thereof | |
MY181731A (en) | Azole benzene derivative | |
MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
MX2021012105A (es) | Compuestos de pirrol. | |
PH12020551297A1 (en) | Compounds having s1p5 receptor agonistic activity | |
MX2022013588A (es) | Combinación de fármacos para tratar la diabetes mellitus y sus complicaciones y composición farmacéutica de la combinación de fármacos. | |
MX2021009971A (es) | Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos. | |
MX2019010108A (es) | Derivados de azetidina. | |
MX2020013729A (es) | Compuestos de cianotriazol y usos de los mismos. | |
MX2022008665A (es) | Nuevo derivado de pirazol. | |
JOP20210319A1 (ar) | مركبات بيروليدين | |
EA202192957A1 (ru) | Дизамещенные пиразольные соединения в качестве ингибиторов кетогексокиназы | |
ZA202303913B (en) | Pyrimidine carboxamide compound and application thereof | |
MX2019015849A (es) | Nuevos compuestos de espirolactona. | |
MX2019004822A (es) | Derivado del pirazol 3,4-bipiridilo y metodo de preparacion del mismo y aplicacion medica del mismo. | |
MX2021001089A (es) | Borato de derivado de azetidina. | |
MX2022001044A (es) | Inhibidor de sglt2/dpp4 y su aplicacion. | |
MX2022001413A (es) | Compuesto de pirimidina-5-carboxamida. |